Literature DB >> 6243443

Supranormal 25-hydroxyvitamin D and subnormal 1,25-dihydroxyvitamin D: their role in X-linked hypophosphatemic rickets.

R W Chesney, R B Mazess, P Rose, A J Hamstra, H F DeLuca.   

Abstract

Serum 25-hydroxyvitamin D (25-OH-D) and 1,25-dihydroxyvitamin D (1,25-(OH)2D) and bone mineral content by the photon-absorption technique were determined in eight patients with X-linked hypophosphatemic rickets treated for at least 24 months with oral sodium phosphate and high-dosage ergocalciferol (vitamin D2). Mean 25-OH-D2 level was 129.5 +/- 67.5 ng/mL (mean +/- SD); the level of 25-OH-D3 was 10.5 +/- 5.8 ng/mL. These values were significantly higher than in normal subjects (total 25-OH-D mean of 27 +/- 10 ng/mL). Serum 1,25-(OH)2D was 16.9 +/- 8.5 pg/mL (mean +/- SD) in the eight patients, significantly lower than 47 +/- 16 pg/mL in 27 age-matched controls. Values indicative of significant demineralization were found in seven of the eight phsophate-treated patients, who had no radiologic evidence of rickets. These results suggest that any theory of the pathogenesis of this disorder must account for inappropriate renal vitamin D metabolism and for renal hyperphosphaturia. The failure of high-dosage oral phosphate and ergocalciferol to fully correct demineralization may suggest a role for calcitriol (1,25-(OH)2D3) as a therapeutic agent.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6243443     DOI: 10.1001/archpedi.1980.02130140014005

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  13 in total

1.  X linked hypophosphataemia: treatment, height gain, and nephrocalcinosis.

Authors:  G S Reusz; P F Hoyer; M Lucas; H P Krohn; J H Ehrich; J Brodehl
Journal:  Arch Dis Child       Date:  1990-10       Impact factor: 3.791

2.  Neurological involvement in X-linked hypophosphataemic rickets.

Authors:  P G Bradbury; D P Brenton; G M Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-06       Impact factor: 10.154

3.  Increased renal catabolism of 1,25-dihydroxyvitamin D3 in murine X-linked hypophosphatemic rickets.

Authors:  H S Tenenhouse; A Yip; G Jones
Journal:  J Clin Invest       Date:  1988-02       Impact factor: 14.808

4.  Effects of age and sex on the regulation of plasma 1,25-(OH)2-D by phosphorus in the rat.

Authors:  R W Gray
Journal:  Calcif Tissue Int       Date:  1981       Impact factor: 4.333

5.  Normal regulation of calcitriol production in Gy mice. Evidence for biochemical heterogeneity in the X-linked hypophosphatemic diseases.

Authors:  G A Davidai; T Nesbitt; M K Drezner
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

6.  Skeletal manifestations of moderate phosphate diabetes.

Authors:  M Laroche; J Arlet; J L Ader; D Durand; T Tran-Van; B Mazières
Journal:  Clin Rheumatol       Date:  1993-06       Impact factor: 2.980

7.  Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and calcitriol.

Authors:  R M Harrell; K W Lyles; J M Harrelson; N E Friedman; M K Drezner
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

8.  Serum 1,25-dihydroxyvitamin D levels in subjects with X-linked hypophosphatemic rickets and osteomalacia.

Authors:  K W Lyles; A G Clark; M K Drezner
Journal:  Calcif Tissue Int       Date:  1982-03       Impact factor: 4.333

9.  Abnormal regulation of renal 25-hydroxyvitamin D-1 alpha-hydroxylase activity in the X-linked hypophosphatemic mouse.

Authors:  B Lobaugh; M K Drezner
Journal:  J Clin Invest       Date:  1983-02       Impact factor: 14.808

10.  Growth hormone secretion in poorly growing children with renal hypophosphataemic rickets.

Authors:  G Saggese; G I Baroncelli; S Bertelloni; G Perri
Journal:  Eur J Pediatr       Date:  1994-08       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.